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Genetics and Epigenetics of the Skin Meet Deep
Sequence
Jeffrey B. Cheng1 and Raymond J. Cho1
Rapid advances in next-generation sequencing tech-
nology are revolutionizing approaches to genomic
and epigenomic studies of skin. Deep sequencing of
cutaneous malignancies reveals heavily mutagenized
genomes with large numbers of low-prevalence
mutations and multiple resistance mechanisms to
targeted therapies. Next-generation sequencing ap-
proaches have already paid rich dividends in identify-
ing the genetic causes of dermatologic disease, both
in heritable mutations and the somatic aberrations
that underlie cutaneous mosaicism. Although epige-
netic alterations clearly influence tumorigenesis, plurip-
otent stem cell biology, and epidermal cell lineage
decisions, labor and cost-intensive approaches long
delayed a genome-scale perspective. New insights into
epigenomic mechanisms in skin disease should arise
from the accelerating assessment of histone modifica-
tion, DNA methylation, and related gene expression
signatures.
Journal of Investigative Dermatology (2012) 132, 923–932; doi:10.1038/
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INTRODUCTION
No longer merely rumblings of a far-off herd, the forerunners
of the DNA sequencing revolution are upon us, trampling
familiar benchmarks. For the past 15 years, genomics has
referred primarily to experiments probing genes or transcripts
using high-density arrays of oligonucleotides. These technol-
ogies recognize millions of prespecified differences in DNA
sequence and RNA abundance. Although arrays may
theoretically tile across gigabases (Bertone et al., 2006),
commercially available versions generally interrogate less
than 2% of the full informational content of a human
genome. Somatic or germline mutations occur virtually
throughout the genome, rendering these technologies of
limited value in detecting new genetic differences. As a
consequence, some of the most basic genetic questions had
remained unresolved: e.g., whether most human cancers
arise from a small number of common mutations or many
combinations of rarer aberrations.
Heritable changes in gene expression may occur without
alteration of DNA sequence, in the form of covalent histone
and DNA modifications, collectively known as epigenetics.
Histone proteins package DNA into nucleosomes and
chromatin fibers. Chemical modifications to histones alter
the recruitment of transcriptional machinery and modulate
gene expression, a layer of regulation known as the ‘‘histone
code’’ (Figure 1a; Jenuwein and Allis, 2001). DNA methyla-
tion also changes the binding and activity of transcriptional
apparatus, often attenuating gene activity in skin and other
tissues (Figure 1b). Until the past few years, genome-wide
epigenetic studies relied heavily on microarray-based meth-
ods with limitations in coverage similar to that for mutational
assessment (e.g., DNA methylation studies using arrays assessed
less than 0.1% of cytosine phosphate guanine (CpG) dinucleo-
tide methylation sites).
With rapid advances in chemistries and imaging technol-
ogy, the so-called ‘‘next-generation sequencing’’ methodol-
ogies (Ansorge, 2009) have reduced the expense in
identifying all 6 billion nucleotides in a diploid genome to
o$4,000, quite recently the bill for a few dozen genes
(Figure 2a). Costs of high-resolution assessment of DNA
methylation and histone modification have dropped propor-
tionately. Bisulfite conversion of unmethylated cytosines to
uracil before sequencing yields true single-nucleotide CpG
resolution for o$4,000. Techniques combining enrichment
of methylated genomic DNA by immunoprecipitation and
methylation-sensitive enzyme digestion, followed by next-
generation sequencing, interrogate B78% of genomic CpGs
for o$1,500 (Harris et al., 2010). Similarly, immunoprecipi-
tation of chromatin DNA bound to specific histone modi-
fications, characterized by next-generation sequencing
(chromatin immunoprecipitation–sequencing), maps these
marks to the genome for as little as $500. In an era of cheap
analytics, the accessibility of cutaneous tissues represents a
distinct advantage. Skin cancers represent a classic model for
somatic mutation, as do rashes for epigenetic alteration.
However, bargain whole-genome analyses tempt us to
inspect and challenge even such basic classifications.
CANCER
Even curable cancers, defying fully predictable response to
therapy, suggest highly individualized genetic etiology. In the
age of Sanger sequencing, before 2008, fewer than 300 genes
were reported to harbor mutations in any cancer (Futreal
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et al., 2004). In the past 3 years, more than 1,000 tumors
representing about 50 classes of malignancy have been
sequenced at large scale—either at the level of the whole
genome, or simply for all known genes (about 50–70 million
bases, or 2–3% of the genome). The catalog has thus
grown by an order of magnitude (Stratton, 2011). To say a
particular primary cancer has been ‘‘deep sequenced’’
now generally implies sufficient redundancy that
changes at more than 90% of inspected nucleotides, and
present in 10% or more cells of the population, can be
detected reliably.
Tumor samples test the limitations of deep sequencing. As
with comparative genomic hybridization and other sequenc-
ing approaches, contamination with stromal or inflammatory
cells rapidly dampens signal, necessitating expensive over-
sampling to detect mutations (Thomas et al., 2006). Read
lengths are short, generally less than 150 bp. Therefore,
multiple mutations in a single gene cannot be ascribed to the
same or different chromosomes without subcloning large
fragments. Short reads also make it difficult to distinguish
genuine mutation in stromal cells from those in the
malignancy. Any amplification approach targeting single or
very small cell populations is hindered by diminished
representation and allele loss (Frumkin et al., 2008).
Nevertheless, given decreasing costs, hundreds of thou-
sands of tumors, as well as matching normal tissue for
comparison, may be comprehensively sequenced by 2020.
Most existing data originated from large collaborative efforts
such as the International Cancer Genome Consortium
(Hudson et al., 2010) and the Cancer Genome Atlas Project,
but improving affordability has opened access to individual
laboratories. As maturing chemistries and solid-state technol-
ogy for sequencing (Mardis and Wilson, 2009; Metzker,
2010) and analytical approaches to mutation detection
(Meyerson et al., 2010) are discussed elsewhere, we focus
on takeaways for the cutaneous oncologist.
Somatic heterogeneity
Although some cancers appear genetically homogenous,
generated from a few predominant aberrations, many appear
driven by hundreds or even thousands of rare combinations
of mutations. The latter profile—several highly prevalent
tumor suppressors or oncogenes, but also a long ‘‘tail’’ of less
frequent somatic changes—typifies cancers as diverse as
pancreatic adenocarcinoma (Jones et al., 2008), glioblastoma
(The Cancer Genome Atlas Research Network, 2008), and
cutaneous melanoma (Wei et al., 2011) (Figure 2b).
Ac Ac Ac
CH3 CH3 CH3 CH3 CH3 CH3
CH3
Figure 1. Epigenetic modifications. (a) Histone modification. Histone
proteins (depicted as blue cylinders) spool DNA (depicted as yellow lines) to
form nucleosomes and chromatin. Posttranslational modifications
(e.g., addition of acetyl, methyl, or ubiqituin groups) to the N-terminal
tail regions of histones alter local chromatin conformation. Variability
in chromatin condensation affects the accessibility of genes. Loosely
condensed regions (euchromatin) are more actively expressed and tightly
condensed regions (heterochromatin) are repressed. Depicted in the
figure is histone acetylation, associated with loosening of local chromatin
and more active gene expression. (b) DNA methylation. DNA methylation
occurs through the addition of a methyl group to the C5 position of
cytosine to form 5-methylcytosine, typically at cytosine phosphate
guanine (CpG) dinucleotides. In promoter regions, DNA methylation
silences genes by interfering with transcription factor binding and/or
recruitment of methyl-CpG-binding proteins that recruit repressor
complexes. DNA methylation is typically associated with tightly
condensed chromatin.
DNA nucleotide bases per $USD
mRNA quantity assessments possible per exome (maximum)
CpG methylation assessments possible per genome (maximum)
0
151184
0.2500
0.5000
0.7500
1.0000
Pr
ev
al
en
ce
 o
f
so
m
a
tic
 m
ut
at
io
ns
Mutated genes
Ovarian adenocarcinoma
Glioblastoma
Melanoma
1
10
102
103
104
105
106
107
108
2000 2005 2010
Figure 2. Rapidly expanding sequence profiles of cancer. (a) For DNA,
graph depicts the number of sequenced nucleotides per $1 USD (NHGRI
2011 data sheet, www.genome.gov/sequencingcosts/). For gene expression
quantification, the number of discrete assessments across all coding regions is
graphed. From 2001 to 2005, the standard Affymetrix (Santa Clara, CA)
platform primarily assessed expression at the 30 ends of transcripts, reaching a
maximum of B50,000 transcripts and variants per array. By 2005, so-called
‘‘exon arrays’’ were introduced, carrying probes for each individual exon,
interrogating expression of more than 250,000 exons. From 2009 to present,
RNA quantification has increasingly been performed using sequencing (RNA-
seq), approximating all46 million coding nucleotides in the human genome.
For cytosine phosphate guanine (CpG) methylation, the primary advances
represent new technologies making denser assessment feasible. Individual
platforms, techniques, and genomic CpG coverage are reviewed in Laird
(2010) and Fouse et al. (2010). (b) Histogram of genetic heterogeneity in
cancer. On the basis of recent sequencing studies, for each cancer type, a
histogram of the most commonly mutated genes are arrayed from most to least
frequent (The Cancer Genome Atlas Research Network, 2008, 2011; Wei
et al., 2011). All non-synonymous mutations per gene were binned; copy
number changes are not displayed.
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Beyond the BRAF oncogene activated in more than half of
primary melanomas arising in sun-damaged skin, sequencing
and copy number analysis have revealed the ERBB4 and
c-KIT signaling receptors as amplified or mutated in
20–30% of primary cancers (Prickett et al., 2009; Flaherty
et al., 2010), as well as NRAS, at similar proportions (Hocker
et al., 2008). For cancers harboring these activated onco-
genes, targeted drugs, such as the Braf inhibitor vemurafenib
and c-kit inhibitor imatinib, have produced striking instances
of clinical response and extended survival (Carvajal et al.,
2011; Chapman et al., 2011). Some novel, low-prevalence
mutations, which may serve as driver oncogenes, appear to
recur in melanoma, such as GRIN2A (glutamate receptor,
ionotropic, N-methyl D-aspartate 2A) (B5%; Wei et al.,
2011), FLT1 (fms-like tyrosine kinase 1), and PTK2B (protein
tyrosine kinase 2b) (B10%; Prickett et al., 2009). Outside
these groups, no well-characterized activating mutation yet
shows a prevalence greater than 5%. Similarly, initial exome
sequencing of cutaneous squamous cell carcinomas has
failed to identify recurrent oncogenic aberrations, even those,
such as in Ras proteins, that commonly produce related
cancers in mouse models (Kemp et al., 1993; Durinck et al.,
2011).
Both melanoma and cutaneous squamous cell carcinomas
tolerate extraordinarily mutated genomes, in cases approach-
ing 100,000 individual base changes per cancer (Pleasance
et al., 2010; Durinck et al., 2011). This frequency eclipses the
several hundred (or fewer) aberrations typically found in
solid cancers. Such high levels of somatic mutations, mainly
generated by ultraviolet radiation, produce legions of so-
called ‘‘passenger’’ changes, obscuring those actually
contributing to malignancy. At observed mutation rates,
5% of average-sized genes (with B1,100 base pairs of
coding sequence) carry a passenger substitution altering
amino acid sequence. Without very large sample sizes, or
recurrence at structurally significant amino acids, low-
prevalence driver candidates in skin require substantive
functional validation.
Once understood, the biology of rare, recurrent aberra-
tions should influence the development of rational therapies.
In the case that dozens of distinct cellular pathways can each
drive malignancy, although infrequently, extending tradi-
tional targeting strategies might take decades. Such a scenario
would be complicated by lower economic incentive and
patient advocacy for unusual genetic origins of cancer. On
the other hand, if many somatic aberrations represent
different points of activation for a few core signaling
pathways, analytical methods detecting such convergence
(Akavia et al., 2010) will prove critical in directing treatment.
The recurrent upregulation (but not mutation) of proteins such
as Polo-like 1 kinase in cutaneous squamous cell carcinomas
may represent targetable instances of such common activated
effector genes (Watt et al., 2011).
The high mutation rate in skin cancers may also generate
synergistic activation of more oncogenic pathways than
found in a corresponding visceral tumor. For example,
disabling mutations in Notch receptors reach 75% preva-
lence in cutaneous squamous cell carcinomas (Wang et al.,
2011), but occur in fewer than 30% of squamous cell
carcinomas of the head, neck, and lung (Agrawal et al., 2011;
Stransky et al., 2011). The cause of this disparity remains
unknown, but we speculate that highly mutagenized cancers
may activate additional pathways requiring combination
strategies in targeted therapies.
Drug resistance
Large-scale cancer sequencing raises expectations for cir-
cumventing acquired drug resistance. The first targeted
inhibitor of the oncogenic hedgehog signaling pathway,
vismodegib, binds and inactivates the G protein–coupled
receptor and oncogene Smoothened (Robarge et al., 2009).
Multiple cancer types activate this pathway, including basal
cell cancers, pancreatic cancers, and medulloblastoma
(Theunissen and de Sauvage, 2009). Unfortunately, more
than 70% of patients treated with systemic vismodegib
develop resistance after 6 months. Comprehensive sequenc-
ing of hedgehog signaling proteins in these resistant cancers
detected new mutations in Smoothened that reduce drug
binding (Yauch et al., 2009).
Similarly, Braf inhibitors rapidly induce responses in even
advanced BRAF-mutant melanomas, but resistance com-
monly (450% of patients) presents within 6 months of
initiation (Chapman et al., 2011). Rather than mutation of the
drug target, as seen in receptors such as Smoothened or
EGFR, vemurafenib-resistant melanomas appear to activate
parallel signaling pathways, via upregulation of the platelet-
derived growth factor receptor-b, or reactivate MEK through
CRAF and oncogenic Ras (Heidorn et al., 2010), MAP3K8
(Johannessen et al., 2010), or gain-of-function mutations in
NRAS (Nazarian et al., 2010). The malignancy rapidly adopts
new machinery to drive growth.
For many cancers, especially of the skin, tumor samples
can be easily accessed before and after treatment. In vemurafenib-
resistant melanoma, BRAF was exhaustively sequenced to rule
out the possibility of new mutations (Nazarian et al., 2010).
Profiling of mRNA transcript levels—now possible through
sequencing-based quantification (RNA-seq)—distinguished
two distinct forms of resistance. Finally, comprehensive
sequencing of defined, candidate oncogenes identified the
new mutations in NRAS. These steps, once the product of
months of labor, can be completed in only a few weeks using
deep sequencing.
As the number of targeted drugs grows, these analytical
capabilities anticipate personalized second-line therapies for
treatment-resistant melanomas, non-melanoma skin cancers,
and cutaneous sarcomas. Crossover strategies have already
shown measurable benefits for sorafenib directed at non-
small cell lung cancers bearing activated forms of KRAS
(Kim et al., 2011).
Epigenomics
Cancers show hypermethylation of CpG-rich regions (so-
called ‘‘CpG islands’’) in promoter regions of tumor
suppressor genes, in a context of global DNA hypomethyla-
tion. Promoter hypermethylation effectively substitutes for
mutational gene inactivation, e.g., leading to loss of tumor
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suppressor gene expression (Nakhasi et al., 1981). In contrast,
hypomethylation may lead to oncogene activation, genomic
instability and chromosomal rearrangements, and/or loss of
parental imprinting (Feinberg et al., 2006). In the Se´zary
syndrome variant of cutaneous T-cell lymphoma, loss of Fas
receptor expression, which in turn suppresses T-cell apopto-
sis, is believed pathogenic (Contassot and French, 2010).
Recent reports suggest DNA hypermethylation as the
most common cause of FAS inactivation, more so than
gene mutation (Jones et al., 2010). In melanoma, at least
90 genes display aberrant DNA methylation, including
genes whose loss-of-function is well established in
melanoma pathogenesis, such as CDKN2A and PTEN
(Sigalotti et al., 2010).
Similarly, dysregulation of histone modifications can
enhance malignancy, presumably through perturbation of
local chromatin structure, thereby altering gene expression.
Among the more well-studied modifications are histone 3
lysine 4 trimethylation (H3K4me3, enriched at the transcrip-
tion start sites of actively expressed genes; Santos-Rosa et al.,
2002) and histone 3 lysine 27 trimethylation (H3K27me3,
associated with gene silencing; Boyer et al., 2006). Gene
rearrangement of MLL (mixed-lineage leukemia), a H3K4
methyltransferase, frequently occurs in leukemias. Mice
engineered to express partially duplicated mixed-lineage
leukemia show increased H3K4me3 levels and associated
overexpression of leukemia-associated genes (Dorrance
et al., 2006). Melanomas often overexpress EZH2 (enhancer
of zeste homolog 2), a H3K27 methyltransferase (Bachmann
et al., 2006), as well as SETDB1 (SET domain, bifurcated 1),
a H3K9 methyltransferase. SETDB1, when overexpressed in
combination with mutant Braf in zebrafish, accelerates
melanoma development, although the end effector genes
are not yet clear (Ceol et al., 2011).
DNA methylation profiles may provide biomarkers for
detection of and prognostication in cancers. In dermato-
pathology, the discovery of epigenetic markers or profiles
may augment the diagnostic capabilities of techniques
currently in use (e.g., immunohistochemistry, comparative
genomic hybridization, or fluorescence in situ hybridization).
Recently, a multi-locus methylation profile discriminated
nevi from melanomas (Conway et al., 2011). Gene hyper-
methylation may also refine prognosis (e.g., PTEN is
hypermethylated in 60% of melanomas and associated with
worse patient survival (Lahtz et al., 2009)).
In other instances, epigenetic changes predict treatment
response. Hypermethylation and loss of expression of MGMT
(O-6-methylguanine-DNA methyltransferase; a DNA repair
enzyme) in glioblastoma multiforme (Costello et al., 1994)
correlates with enhanced survival from alkylating agent
chemotherapy (Hegi et al., 2005). Unfortunately, MGMT
status in metastatic melanoma does not predict response to
the commonly used alkylating agent, dacarbazine (Hassel
et al., 2010).
Finally, modulating epigenetic activity can treat disease.
Currently, the histone deacetylase inhibitors vorinostat and
romidepsin are Food and Drug Administration approved
for treatment of cutaneous T-cell lymphomas. Similarly,
azacitidine and decitabine (DNA methyltransferase inhibi-
tors) are approved for hematological malignancies (Boumber
and Issa, 2011). The mechanisms underlying these agents are
not understood completely. For example, histone deacetylase
inhibitors not only block histone deacetylases but also
increase acetylation of other structural proteins and transcrip-
tion factors (Lane and Chabner, 2009).
Earlier, low-resolution studies of a mouse skin carcinogen-
esis model show global changes in epigenetic marks with
early and progressive accumulation of DNA hypomethylation
and loss of acetylation at Lys16 and trimethylation at Lys20 of
histone H4 (Fraga et al., 2004, 2005). In addition, hyper-
methylation of tumor suppressor genes (e.g., MLH1, mutL
homolog 1), VHL (Von Hippel–Lindau), and p16INK4a) often
occurs early in tumorigenesis (Jones and Baylin, 2002). The
mechanisms underlying both these specific and more global
DNA methylation and histone modification alterations
remain unclear (Feinberg and Tycko, 2004). The next 5 years
should mark completion of many high-resolution epigenomes
and genomes from normal, premalignant, and malignant
tissues. These data should help determine which alterations
affect disease and whether they result from mutations in
epigenetic machinery, develop sporadically under selective
pressure, and/or are secondary to other processes in
tumorigenesis.
GENETIC DISEASE
Somatic mosaicism
Dermatologists are practiced skeptics of the dogma ‘‘one
genome per individual’’. Genetic diversity within individuals
reveals itself routinely in skin: the mosaic presentations of
X-linked conditions such as incontinentia pigmenti and
McCune-Albright disease (Rieger et al., 1994); localized
lesions of neurofibromatosis or Darier disease (Kehrer-
Sawatzki and Cooper, 2008; Harboe et al., 2011); and even
the abundant nevi harboring BRAF mutations (Lin et al.,
2011). Most of these examples result from single-nucleotide
changes. Simple mutation, given its potential to finely modify
any gene at any position, may represent the most common
source of somatic mosaicism. Indeed, deep sequencing has
recently revealed that nucleotide substitutions generate the
striking segmental presentation of the Proteus syndrome
(Lindhurst et al., 2011).
Recently, cheaper sequencing identified a novel mechan-
ism of somatic diversity. Ichthyosis en confetti, a rare defect
in keratinization, is distinguished by macules of apparently
normal skin. These islands represent true reversion of
mutations in the keratin 10 gene through mitotic recombina-
tion of chromosome 17 (Choate et al., 2010). Such copy-
conservative chromosomal duplication is well established,
known as ‘‘isoparental disomy’’ in heritable genetics and
‘‘copy-neutral loss-of-heterozygosity’’ in cancer, but this
discovery reveals an assiduous process in normal adult cells.
Such somatic instability appears at least partially position
specific (as in chromosome 17), as none of the other keratin-
based ichthyosiform disorders demonstrate such common
reversion. Sequence-dependent mechanisms that may
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underlie such chromosomal aberration have recently been
proposed (De and Michor, 2011).
Chromosomal duplication conferring reversion may also
correct inherited blistering disorders, albeit only focally.
Some of these patches of reversion result from the types of
chromosomal displacement described in ichthyosis en
confetti, erasing dominant alleles encoding structural defects
(Jonkman et al., 1997; Pasmooij et al., 2005). Surprisingly,
single-nucleotide insertions and deletions may also, on
occasion, precisely edit inherited mutations in collagens
and laminins (Jonkman et al., 2003; McGrath, 2004).
These diverse examples imply that occult, localized
genetic variation probably both enhances and ameliorates
human pathology constantly (Cho, 2010). Detecting small
populations of mutant cells demands the screening of
exomes for aberrant populations less than 1 in 10,000
affordably and reliably. Continued gains in ultra-deep
sequencing efficiency may surpass this threshold in the
next 10 years.
Inherited disease
Traditional genome-wide association studies (GWAS) profile
genetic polymorphism in individuals with and without
heritable conditions such as psoriasis. Some of these single-
nucleotide polymorphisms recurrently associate with disease;
the chromosomal neighborhood of these markers is then
scoured for potential causative genes. During the past 10
years, the improved ability to type markers and organize
large-scale studies of affected populations have greatly
expanded candidate loci contributing to common diseases
such as diabetes, cardiovascular disease, and psoriasis
(Stranger et al., 2011). However, many GWAS identified loci
have not been linked definitively to causative genes, as
markers often flank large regions spanning many genes. New,
population-based approaches linking genotype to phenotype
may accelerate the functional annotation and validation of
such candidates (Dendrou et al., 2009).
In psoriasis, a large number of studies have confirmed the
immunological loci HLAA, HLAB, and HLAC as the genomic
regions most strongly associated with classic psoriasis
vulgaris (Nair et al., 2006; Liu et al., 2008). Remarkably, it
appears that the greatest genetic contributions to a common
disease were identified decades in advance of unbiased
genome-wide screening (Rimbaud et al., 1974). However,
genome-wide association studies have expanded the list of
candidate effectors to polymorphisms in the IL12/23 complex
subunits (targets of highly specific new targeted drugs for
psoriasis such as ustekinimab; Cargill et al., 2007; Zhang
et al., 2009) and also new pathways such as defensin-
mediated immunity (Hollox et al., 2008) whose clinical
significance is not yet clear.
Exome sequencing seems poised to supplant array-based
genome-wide association studies (Figure 3a). Deep sequen-
cing retrieves not only portions of chromosomes associated
with disease but also those nucleotide variants potentially
altering protein sequence. If samples reveal particularly
consequential changes to a gene, a small number of affected
individuals may suffice to identify the causative gene. In only
the past 12 months, exome sequencing has been used to
identify novel causative mutations for conditions as diverse as
oculocutaneous albinism with neutropenia (Cullinane et al.,
2011), familial hypotrichosis (Zhou et al., 2011a), and
hidradenitis suppurativa (Wang et al., 2010), often from
limited kindreds (Figure 3b).
EPIGENETIC CONTROL OF CELL FATE
Although an individual’s stem cells are essentially genetically
identical, regardless of tissue of origin, epigenetic mechan-
isms critically maintain the stem cell state and direct
subsequent differentiation. Embryonic stem (ES) cells, derived
from the inner cell mass of the blastocyst, self-renew
indefinitely, and as pluripotent cells, give rise to all cell
types of the body. Thus, these populations offer unique
insight into early developmental biology and suggest possible
therapeutic cell replacement. ES cells harbor such character-
istic epigenetic features as ‘‘bivalent domains’’ in promoters
of early developmental genes, where both activating
H3K4me3 and repressive H3K27me3 histone modifications
reside. Consequently, these genes may lie silent but
responsive to developmental stimuli (Mikkelsen et al., 2007).
With cell fate determination, increased expression of
lineage-specific genes associates with loss of H3K27me3
marks, whereas genes for other lineages are not expressed
and maintain their bivalent marks, or lose H3K4me3 at
their promoters (Mikkelsen et al., 2007; Pan et al., 2007).
Similar mechanisms influence the maintenance and differ-
entiation of skin progenitor cells. In proliferating human
keratinocytes, H3K27me3 is enriched at the promoters of and
presumably represses transcription of epidermal differentia-
tion genes. During differentiation, a subset of these genes
(e.g., keratin 1 and involucrin) lose repressive H3K27me3
marks with upregulation of their gene products (Sen et al.,
2008).
DNA methylation patterns also associate with differing
states of cellular identity. In ES cells, genes associated with
pluripotency tend to be hypomethylated, whereas those
associated with differentiation tend to be hypermethylated
and inactive (Huang and Fan, 2010). For somatic progenitor
and stem cells, DNA methylation appears required for
maintenance of cell renewal. Depletion of DNA methyl-
transferase-1 (an enzyme that maintains DNA methylation
marks) in human epidermal progenitor cells leads to cell
cycle arrest, premature differentiation, and loss of self-
renewal. These changes correspond with loss of promoter
DNA methylation at epidermal differentiation genes with
differentiation (Sen et al., 2010). During differentiation,
numerous genetic loci undergo changes in methylation,
likely promoting lineage commitment by repressing genes
related to other lineages and leaving lineage-specific genes
hypomethylated and expressed (Huang and Fan, 2010). For
example, during hematopoietic myeloid cell specification,
genes important for myeloid development such as GADD45a
(growth arrest and DNA-damage-inducible a) and myeloper-
oxidase become hypomethylated and upregulated (Ji et al.,
2010)). In skin cells, primary cultured KCs grown under low
calcium basal conditions show DNA hypomethylation of the
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keratin 5 locus, whereas primary cultured fibroblasts show
hypermethylation (Figure 4).
Given their similar roles in regulating gene expression
programs, the significant interplay between histone modifica-
tions and DNA methylation is not surprising. Histone
modifications appear more dynamic. DNA methylation
functions as a more stable regulatory mechanism to lock in
these expression programs (Cedar and Bergman, 2009).
Additional layers of regulation are evident; e.g., the long
noncoding RNA HOTAIR interacts with the Polycomb
repressive complex 2 (which mediates histone H3 lysine 27
methylation) to help specify expression programs associated
with fibroblast anatomic positional identity (Rinn et al.,
2007).
Induced pluripotent stem cells (iPSCs) illustrate the impor-
tance of epigenetic mechanisms in maintaining cellular state,
as somatic cells can be epigenetically reprogrammed back to
an embryonic cell–like state through the expression of certain
transcription factors (e.g., Oct 3/4, Sox2, krueppel-like
factor 4, and c-Myc; Wu and Hochedlinger, 2011). Induced
pluripotent stem cells embody features of true ES cells such as
morphology, stem cell gene expression, and ability to
differentiate into many cell lineages, but circumvent ethical
issues associated with ES cells. Their potential clinical
benefits include use in tissue regeneration, disease modeling,
and gene therapy (Galach and Utikal, 2011). Cutaneous
diseases may be among the earliest to benefit from the use of
iPSCs through autologous replacement of diseased skin with
genetically corrected skin. Mutations in the collagen VII gene
cause recessive dystrophic epidermolysis bullosa, a cuta-
neous blistering disease with devastating clinical conse-
quences. Recent reports of iPSC generation from these
patients, differentiation into KCs and skin-like structures,
and reengineering of these KCs to express functional collagen
VII provide an early proof of principle (Itoh et al., 2011; Tolar
et al., 2011).
Despite the great potential of iPSCs, similarity to ES cells
may not be complete. Initial maps show hundreds of
differentially methylated DNA regions between ES cells and
iPSCs, which may partly represent an epigenetic memory
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Figure 3. Accelerating gains in correlating genotype to phenotype. (a) For chromosome 11, distribution of interrogated DNA sequence displayed for (A)
microsatellite markers (1993), (B) single-nucleotide polymorphisms on Affymetrix 100K genotypic oligonucleotide array (2004), and (C) whole exome
(2010). (b) Genetic bases of recent cutaneous phenotypes identified by exome sequencing Affymetrix, USA (Sun et al., 2010; Concolino et al., 2010; Wang et al.,
2010; Goudie et al., 2011; Auer-Grumbach et al., 2011; Zhou et al., 2011a; Shaheen et al., 2011; Lindhurst et al., 2011; Liu et al., 2011; Cullinane et al., 2011).
Closed diamonds show activating mutations; open diamonds represent loss-of-function mutations.
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from the original somatic cell type, with incomplete DNA
methylation reprogramming (Lister et al., 2011). Observed,
subtle differences in gene expression may share a similar
cause (Ohi et al., 2011; Ghosh et al., 2010). These residual
epigenetic marks may explain why low-passage iPSCs
preferentially differentiate into lineages related to their
original somatic cell type and restrict alternative cell lineages
(Kim et al., 2010; Polo et al., 2010).
EPIGENETICS ON A GENOME SCALE
Different cell types, individuals, and disease states develop
unique epigenomes. Methodological limitations of older
DNA methylation studies constrained analysis to CpG islands
and promoter regions, largely ignoring the remainder of the
genome. Deep sequencing appears to be the likeliest path to
expanding the catalog of differences distinguishing cell types
(e.g., KCs and fibroblasts) and elucidating their significance.
A number of collaborative efforts (e.g., the International
Human Epigenome Consortium, Encyclopedia of DNA
Elements (Encode), Blueprint and NIH Roadmap Epigenomics
projects) seek to bring hundreds of such ‘‘reference epigen-
omes’’ to the community during the next 10 years.
This high-resolution cartography of genome-wide DNA
methylation in normal tissue and tumors has begun. Early,
surprising findings include underappreciated rates of non-
CpG methylation (Lister et al., 2009), the intragenic and
intergenic addresses (rather than 50 promoter regions) of most
differentially methylated CpG islands (Maunakea et al.,
2010), and the fact that CpG island shores (low CpG density
regions that lie up to 2Kb from CpG islands) show highly
variant methylation. The significant overlap of differentially
methylated CpG island shore locations between different
tissue types and normal tissue and cancers suggests dysregu-
lated tissue-specific DNA methylation mechanisms in malig-
nancy (Irizarry et al., 2009).
DNA methylation may not correlate only with decreased
expression. Gene body methylation appears to regulate
cell type–specific alternative promoters/transcripts and can
increase gene expression (Laurent et al., 2010; Maunakea
et al., 2010). New gene expression profiling techniques
such as RNA-seq assess these tissue-specific alternative
transcripts (observed in B98% of multi-exon genes) and
non-annotated regions at far higher resolution (Wang et al.,
2008).
Genome-wide histone modification maps based on
ChIP-seq should further dissect the machinery determining
these marks and their regulatory roles in different cell types
and development (e.g., H3K4me1 associates with active
and poised enhancers, H3K4me3 with active promoters, and
H3K36me3 with actively transcribed gene bodies). Given the
complex interplay between DNA methylation, histone
modification, and subsequent gene regulation, we anticipate
discovery of new, coordinated changes in epigenetic patterns
that drive cutaneous tumorigenesis, maintenance of stem cell
renewal, and cell fate decision.
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